Iveric bio, inc. (ISEE)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Dec'12
Assets
Current assets
Cash and cash equivalents

108,400

125,700

94,900

106,889

116,600

131,200

135,208

145,991

154,911

166,972

180,217

140,917

92,554

133,930

165,604

194,054

183,822

221,861

254,895

36,720

39,568

39,814

94,804

248,498

66,562

210,596

236,079

4,304

Accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

50,000

-

-

-

-

-

Available for sale securities

-

-

-

-

-

-

-

-

-

-

0

55,525

135,061

155,348

155,552

104,658

109,104

74,731

26,147

412,320

393,718

423,746

313,978

188,733

196,500

-

-

-

Due from Novartis Pharma AG

-

-

-

-

-

-

-

-

-

-

0

674

3,531

3,531

6

30,197

10,062

4,389

-

247

50,249

960

-

-

-

-

-

-

Prepaid expenses and other current assets

2,183

2,043

1,110

1,937

2,395

2,086

2,055

1,919

2,836

3,146

1,436

2,738

4,650

3,078

1,514

1,896

2,299

5,504

5,541

10,885

8,900

8,812

2,793

4,087

5,270

6,804

2,096

44

Income tax receivable

4,706

882

1,012

1,765

-

0

0

0

0

1,387

-

-

-

0

24,265

24,283

26,497

-

-

-

-

-

-

-

-

-

-

-

Deferred tax assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,500

106

70

-

1,069

837

-

-

-

-

Other Assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

331

Security deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

158

Security deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

158

-

Total current assets

115,241

128,624

96,973

110,591

119,034

133,287

137,263

147,910

157,747

171,505

181,653

199,854

235,796

295,887

346,941

355,088

331,784

306,485

288,083

460,278

492,505

473,332

462,644

442,155

268,332

217,400

238,333

4,837

Available for sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

27,011

63,211

95,298

144,944

-

-

-

-

15,255

27,763

-

-

-

Property and equipment, net

135

173

212

252

292

335

379

424

468

518

1,302

1,888

2,473

3,281

3,174

3,263

3,350

3,466

2,590

1,809

1,563

1,555

1,289

826

743

27

32

42

Right-of-use asset, net

326

496

745

989

1,230

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax receivable, non-current

0

882

882

1,765

3,529

3,529

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred tax assets

-

-

-

-

-

-

3,296

3,296

3,296

3,529

-

-

-

0

0

-

-

23,113

-

-

-

-

-

-

-

-

-

-

Deferred tax assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14,632

8,443

4,412

4,517

26,187

19,635

-

-

-

-

Security deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

467

467

282

-

282

255

255

255

-

-

Other assets

12

12

11

11

11

14

19

31

40

24

27

46

3

462

470

492

500

489

35

52

79

382

84

-

-

-

11

-

Total assets

115,714

130,187

98,823

113,608

124,096

137,165

140,957

151,661

161,551

175,576

182,982

201,788

238,272

299,630

350,585

385,854

398,845

428,851

450,751

471,049

498,841

479,786

490,486

478,126

297,093

217,682

238,376

4,879

Liabilities and Stockholders' Equity
Current liabilities
Accrued research and development expenses

8,384

6,860

4,950

7,645

5,910

7,337

5,916

5,137

5,196

4,984

6,212

12,687

27,955

47,240

40,017

25,151

21,727

18,820

20,080

9,775

8,103

7,918

-

-

-

-

-

-

Accrued clinical drug supplies and trial costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,342

1,783

2,802

2,485

3,477

1,013

Accounts payable and accrued expenses

2,375

5,629

3,666

3,241

2,987

5,869

4,614

3,994

3,278

7,551

7,895

6,268

8,657

12,032

10,389

7,769

7,287

12,018

7,850

6,150

5,757

8,707

6,706

4,039

3,753

3,810

4,431

1,391

Lease liability

219

495

745

989

985

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

0

6,646

6,646

6,646

6,776

6,776

5,212

6,667

6,714

6,755

6,637

3,206

3,206

-

-

-

-

-

Income tax payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,785

29,540

-

-

-

-

Notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,040

Warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

966

Total current liabilities

10,978

12,984

9,361

11,875

9,882

13,206

10,530

9,131

8,474

12,535

14,107

25,601

43,258

65,918

57,182

39,696

34,226

37,505

34,644

22,680

20,497

19,831

24,039

35,362

6,555

6,295

7,908

14,410

Operating Lease, Liability, Noncurrent

106

0

-

-

245

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue, long-term

-

-

-

-

-

-

-

-

-

-

0

200,007

201,669

203,330

204,992

206,653

206,396

206,399

207,996

209,593

211,309

206,418

207,219

-

-

-

-

-

Deferred revenue, long-term

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

200,000

-

-

-

-

Royalty purchase liability

-

-

-

-

-

-

125,000

125,000

125,000

125,000

125,000

125,000

125,000

125,000

125,000

125,000

125,000

125,000

125,000

125,000

125,000

125,000

83,333

83,333

83,333

41,667

41,667

-

Total liabilities

11,084

12,984

9,361

11,875

10,127

13,206

135,530

134,131

133,474

137,535

139,107

350,608

369,927

394,248

387,174

371,349

365,622

368,904

367,640

357,273

356,806

351,249

314,591

318,695

89,888

47,962

49,575

14,410

Total Preferred Stock, Convertible and Redeemable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

113,939

Stockholders' equity
Preferred stock—$0.001 par value, 5,000,000 shares authorized, no shares issued or outstanding

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

-

Common stock—$0.001 par value, 200,000,000 shares authorized, 49,731,811 and 49,627,064 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

50

50

42

41

41

41

36

36

36

36

36

36

36

36

36

36

35

35

35

35

34

34

34

33

33

31

31

1

Additional paid-in capital

600,182

597,679

552,468

550,303

548,096

545,585

531,172

528,530

525,868

522,759

519,051

515,615

510,612

504,517

496,210

486,372

475,024

465,924

452,887

444,034

435,204

428,390

421,193

415,604

410,886

352,739

351,431

-

Accumulated deficit

-495,602

-480,526

-463,048

-448,611

-434,168

-421,667

-525,781

-511,036

-497,827

-484,754

-475,212

-664,285

-642,081

-598,959

-532,676

-471,785

-441,840

-405,539

-369,890

-330,317

-293,186

-299,822

-245,367

-

-

-

-

-

Accumulated deficit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

256,231

203,732

183,050

162,661

126,471

Accumulated other comprehensive loss

-

-

-

-

-

-

-

-

-

-

0

-186

-222

-212

-159

-118

4

-473

79

24

-17

-65

35

25

18

-

-

-

Total stockholders' equity

104,630

117,203

89,462

101,733

113,969

123,959

5,427

17,530

28,077

38,041

43,875

-148,820

-131,655

-94,618

-36,589

14,505

33,223

59,947

83,111

113,776

142,035

128,537

175,895

159,431

207,205

169,720

188,801

-123,470

Total liabilities and stockholders' equity

115,714

130,187

98,823

113,608

124,096

137,165

140,957

151,661

161,551

175,576

182,982

201,788

238,272

299,630

350,585

385,854

398,845

428,851

450,751

471,049

498,841

479,786

490,486

478,126

297,093

217,682

238,376

4,879